The high-grade B-cell lymphomas: double hit and more
Edited by Associate Editor Michael Hallek and Podcast Editor Laurie H. Sehn, this Review Series highlights the biologic features of, clinical phenotype of,
Related Articles
Elacestrant Shows Tolerability in Combination With CDK4/6, PI3K Inhibitors in Advanced ER+ Breast Cancer
Elacestrant was partnered with multiple targeted agents across varying dose levels and schedules for patients with estrogen receptor–positive advanced breast cancer.
Turning grief into purpose
Full of stamina and determination, Lynn Lippert supported others and did what she loved through 24 years of living with metastatic breast cancer. Lippert’s life…
Healing Visual Arts Program Offers New Strategy for Artwork at Fox Chase Cancer Center and Network Locations
Art remains a vital part of Fox Chase Cancer Center’s culture. From the symbolic sculpture, The Diamond, greeting visitors outside the main entrance to the…
An Overview of the Treatment Landscape for Anemia Management in LR-MDS
Thomas W. LeBlanc, MD, MA, discusses how the standard of care (SOC) options for anemia management in patients with low-risk myelodysplastic syndromes (LR-MDS) typically involve…
Autologous HCT Does Not Provide Added Survival Benefit in Patients With MCL in First CR
Results of the EA4151/BMT-CTN 1601 trial showed similar progression-free and overall outcomes with the addition of autologous transplant to rituximab in mantle cell lymphoma.
What is the Whipple procedure? Explaining Randy Moss’ cancer surgery
Pancreatic cancer survival rates have more than doubled in the past decade. It’s not because of a single breakthrough, but better knowledge of the cancer,…
Axi-Cel Sustains Long-Term Efficacy in R/R Follicular Lymphoma and MZL
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
2024 Most Read Articles | Blood | American Society of Hematology
2024 Most Read Articles | Blood | American Society of Hematology Top Ten Most Read Articles in 2024 Blood is pleased to announce the following…
The year in cancer: 24 advances in 2024
By W. Kimryn Rathmell Director, National Cancer Institute Dr.
